Critical review for report shows a model to consider the cost-effectiveness of a disease.

Nuijten and colleagues (Pharmacoeconomics 2007 vol 25 no 1 pp 55-71) (attached copy) report a model to consider the cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children. Assuming that the clinical details reported are correct, and concentrating on the modelling aspect of the work, do you find the results convincing? What alternative approaches to the modelling, analysis and presentation of the results might be appropriate in this case?